Business Context and Reporting Period
Company: Oragenics, Inc.
Filing Type: Form 10-QSB (Quarterly Report)
Period Ended: September 30, 2003
Business Overview: Oragenics is a biotechnology company dedicated to developing genetically engineered Streptococcus mutans for oral and therapeutic applications. The company completed its Initial Public Offering (IPO) on June 24, 2003, raising approximately $2.3 million in net proceeds.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2003 | Nine Months Ended Sep 30, 2003 | Balance Sheet (Sep 30, 2003) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(396,722) | $(1,045,483) | N/A |
| Operating Expenses | $398,426 | $1,038,765 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $1,693,147 |
| Total Assets | N/A | N/A | $1,820,622 |
| Total Liabilities | N/A | N/A | $236,434 |
| Stockholders' Equity | N/A | N/A | $1,584,188 |
| Net Cash Used in Operating Activities | N/A | $(780,418) | N/A |
| Net Cash Provided by Financing Activities | N/A | $2,488,862 | N/A |
Material Changes vs. Prior Period
- Operating Expenses: Increased 134% for the three months ended September 30, 2003, compared to the same period in 2002. For the nine-month period, expenses rose 105%.
- Research & Development (R&D): R&D expenses surged 101% (three months) and 181% (nine months). Drivers included hiring additional staff, stock-based compensation, regulatory consulting, and a one-time $100,000 payment to the University of Florida for patent filings.
- General & Administrative (G&A): G&A expenses increased 183% (three months) and 50% (nine months), attributed to CEO salary increases, stock-based compensation, and directors' and officers' liability insurance.
- Liquidity: Cash balances grew from $25,580 at year-end 2002 to $1,693,147 at September 30, 2003, primarily due to IPO proceeds and warrant exercises.
- Net Loss: Net loss for the nine months ended September 30, 2003, was $1,045,483, compared to $511,658 in the prior year period.
Guidance, Outlook, and Risks
- Capital Resources: Management anticipates that the net proceeds from the IPO (~$2.3 million) will be sufficient to cover operating expenses and capital requirements through 2004.
- Future Funding Needs: The company expects to incur substantial additional expenses for R&D, preclinical testing, and clinical trials. Future funding will likely be sought through sublicensing arrangements or public/private financings, though no assurance of availability exists.
- Debt Facilities: The company has a loan facility with Cornet Capital Corp. allowing for up to $500,000 in additional borrowing if required. Previous loans of $175,000 were repaid in June 2003 using IPO proceeds.
- Warrants: As of September 30, 2003, 2,768,500 warrants were outstanding. If exercised, they could provide up to $6.4 million in proceeds, though there is no assurance they will be exercised.
- Risks: The company has no revenue and relies entirely on financing. Risks include the ability to secure additional funding, the success of clinical trials, and regulatory approval timelines.
Key Facts for Investor Verification
- Revenue Status: The company has generated zero revenue to date and is in the pre-revenue development stage.
- Burn Rate: Operating cash burn was approximately $780,000 for the nine months ended September 30, 2003.
- One-Time Costs: A significant portion of the 2003 R&D increase ($100,000) was a one-time patent repayment to the University of Florida.
- Stock-Based Compensation: The company recorded $170,291 in stock-based compensation expense for the nine months ended September 30, 2003, which is a non-cash charge impacting net loss.
- Warrant Expiration: Outstanding warrants have exercise prices ranging from $1.25 to $3.00 and expire between December 2003 and June 2005.